重组人血管内皮抑素联合肝动脉化疗栓塞治疗结直肠癌术后肝转移的临床应用

Recombinant human endostatin combined with transcatheter arterial chemoembolization in treatment of liver metastasis of colorectal cancer

目的探讨重组人血管内皮抑素联合肝动脉化疗栓塞(TACE)治疗结直肠癌术后肝转移的临床疗效与安全性。方法 32例结直肠癌术后肝转移患者分为治疗组和对照组,治疗组采用重组人血管内皮抑素联合TACE治疗,对照组常规TACE治疗,两次治疗间隔1月。3周期后,按照RECIST标准评价疗效,观察Karnofsky评分(KPS)、CEA表达水平变化情况,对相关数据进行统计学分析。结果两组术后均无CR患者,治疗组在治疗效果、K氏评分明显好于对照组,CEA表达水平与对照组比较差异均有统计学意义(P<0.05)。不良反应与对照组比较差异无统计学意义(P>0.05)。结论重组人血管内皮抑素联合肝动脉化疗栓塞治疗结直肠癌术后肝转移可以改善患者K氏评分,提高治疗有效率及疾病控制率,且不良反应小,安全性好,长期结果有待进一步观察。

Objective To investigate the efficacy and safety of recombinant human endostatin combined with transcatheter arterial chemoembolization（TACE） in treatment of liver metastasis of colorectal cancer.Methods Thirty-two patients with liver metastasis of colorectal cancer were treated with recombinant human endostatin combined with TACE（trial group） or TACE alone（control group）with 16 cases in each group;the treatment was repeated in one month interval.After three therapeutic cycles,the clinical effect was evaluated with RECIST criteria,and the Karnofsky scoring,the plasma CEA levels were measured.Results There were no CR patients in both groups.The disease control rate and the Karnofsky scores were significantly higher in trial group than those in control group（P0.05） and there were significant differences in plasma CEA levels between two groups（P0.05）.Adverse reactions were mild and there was no significant difference between two groups（P0.05）.Conclusion Recombinant human endostatin combined with TACE can improve Karnofsky scores and disease control rate with few adverse effects for patients with liver metastasis of colorectal cancer.